MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Intra-Cellular Therapies Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

131.89 -0.02

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

131.81

Max

131.97

Pagrindiniai rodikliai

By Trading Economics

Pajamos

9.4M

-17M

Pardavimai

24M

199M

Pelnas, tenkantis vienai akcijai

-0.16

Pelno marža

-8.475

Darbuotojai

860

EBITDA

9.8M

-29M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

-0.83% downside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.8B

14B

Ankstesnė atidarymo kaina

131.91

Ankstesnė uždarymo kaina

131.89

Naujienos nuotaikos

By Acuity

77%

23%

352 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Intra-Cellular Therapies Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-01-13 12:11; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal

2025-01-13 11:40; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson in Talks to Acquire Intra-Cellular Therapies, Says Bloomberg

2025-03-14 09:30; UTC

Svarbiausios naujienos

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

2025-01-22 14:09; UTC

Svarbiausios naujienos
Uždarbis

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

2025-01-22 11:22; UTC

Svarbiausios naujienos
Uždarbis

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

2025-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug -- IBD

2025-01-13 20:12; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- Update

2025-01-13 16:18; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- WSJ

2025-01-13 15:57; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal -- Barrons.com

2025-01-13 14:10; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal -- IBD

2025-01-13 12:25; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

2025-01-13 11:57; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson Confirms $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

2025-01-13 11:56; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

2025-01-13 11:45; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson: Intra-Cellular's Clinical-Stage Pipeline Has Best-In-Disease Potential in Generalized Anxiety Disorder, Alzheimer's Treatments >JNJ

2025-01-13 11:43; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson: Caplyta Solidifies Sales Above Analyst Expectations Through Remainder of Decade>JNJ

2025-01-13 11:43; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson: Caplyta Has Potential of Over $5 Billion in Peak Yr Sales >JNJ

2025-01-13 11:42; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson Purchases Intra-Cellular for $132/Shr in Cash, or About $14.6B >JNJ

2025-01-13 11:41; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson: SNDA Submitted to FDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder >JNJ

2025-01-13 11:40; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson: Acquisition Includes CaplytaTreatment for Bipolar I and II Depression, Schizophrenia >JNJ

2025-01-13 11:34; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson: Deal Adds Intra-Cellular's Caplyta Depression Drug >JNJ ITCI

2025-01-13 11:32; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson: To Maintain Strong Balance Sheet, Continue to Support Capital-Allocation Priorities >JNJ

2025-01-13 11:32; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson To Fund Transaction With Cash on Hand, Debt >JNJ ITCI

2025-01-13 11:31; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson to Buy Intra-Cellular Therapies for About $14.6 Billion >JNJ ITCI

2025-01-13 11:31; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson to Buy Intra-Cellular Therapies for $132/Share in Cash >JNJ ITCI

2025-01-13 11:30; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson Strengthens Neuroscience Leadership With Acquisition Of Intra-Cellular Therapies, Inc. >JNJ ITCI

2025-01-13 10:55; UTC

Įsigijimai, susijungimai, perėmimai

This Stock Is Soaring Amid Johnson & Johnson Takeover Report -- Barrons.com

2025-01-13 10:41; UTC

Įsigijimai, susijungimai, perėmimai

This Stock Is Soaring Amid J&J Takeover Report. What to Know. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Intra-Cellular Therapies Inc Prognozė

Kainos tikslas

By TipRanks

-0.83% į apačią

12 mėnesių prognozė

Vidutinis 130.83 USD  -0.83%

Aukščiausias 132 USD

Žemiausias 118 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Intra-Cellular Therapies Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

13 ratings

4

Pirkti

9

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

131.69 / 131.92Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

No Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

352 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.